within Pharmacolibrary.Drugs.ATC.B;

model B03AB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.011666666666666665,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ferric sodium citrate is an iron salt used primarily as an oral phosphate binder in the management of hyperphosphatemia, particularly in patients with chronic kidney disease on dialysis. It provides a source of iron for absorption and aids in reducing phosphate absorption from the gut. Ferric sodium citrate is approved and used therapeutically, especially in Japan.</p><h4>Pharmacokinetics</h4><p>There are no published studies that provide detailed compartmental pharmacokinetic parameters for ferric sodium citrate in humans. The values below are estimated for an adult population receiving a typical oral dose for phosphate binding.</p><h4>References</h4><ol><li><p>Motoya, T, et al., &amp; Yamada, K (2000). Effects of ascorbic acid on interactions between ciprofloxacin and ferrous sulphate, sodium ferrous citrate or ferric pyrophosphate, in mice. <i>The Journal of pharmacy and pharmacology</i> 52(4) 397–401. DOI:<a href=&quot;https://doi.org/10.1211/0022357001774147&quot;>10.1211/0022357001774147</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10813549/&quot;>https://pubmed.ncbi.nlm.nih.gov/10813549</a></p></li><li><p>Schmid, A, et al., &amp; Keul, J (1996). Effect of physical exercise and vitamin C on absorption of ferric sodium citrate. <i>Medicine and science in sports and exercise</i> 28(12) 1470–1473. DOI:<a href=&quot;https://doi.org/10.1097/00005768-199612000-00005&quot;>10.1097/00005768-199612000-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8970140/&quot;>https://pubmed.ncbi.nlm.nih.gov/8970140</a></p></li><li><p>Kokado, Y, et al., &amp; Kondo, K (2021). In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor. <i>Clinical therapeutics</i> 43(8) 1408–1418.e5. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2021.06.013&quot;>10.1016/j.clinthera.2021.06.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34511184/&quot;>https://pubmed.ncbi.nlm.nih.gov/34511184</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B03AB01;
